Published in Vaccine Weekly, November 21st, 2001
Erbitux is an investigational monoclonal antibody designed to target and block the epidermal growth factor receptor (EGFR), which is expressed on the surface of certain cancer cells, including colon cancer. Bristol-Myers Squibb and ImClone Systems recently announced an agreement to codevelop and copromote Erbitux in the United States, Canada, and Japan.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.